Abstract

Yeast contributions to Alzheimer’s Disease

Highlights

  • Alzheimer’s diseaseGlobally, 50 million cases of cognitive impairment are associated with Alzheimer’s disease (AD), the most common form (60-80%) of dementia and major cause of death in elderly people

  • It is paramount to improve our understanding of AD to facilitate the identification and development of therapeutic strategies to treat or prevent the disease

  • AD is characterised by the accumulation of toxic proteins, including amyloid beta and tau that impact key molecular and cellular functions

Read more

Summary

Introduction

50 million cases of cognitive impairment are associated with Alzheimer’s disease (AD), the most common form (60-80%) of dementia and major cause of death in elderly people. This number is expected to triple to 152 million by 20501,2,3. In addition to AD’s profound impact on quality of life, the disease is a major healthcare, economic and social burden. It was reported in America alone, in 2018, an estimated 18.5 billion hours of care was provided by unpaid care workers and family members for those suffering from AD2. J Human Clin Gen (2020);2(2):[2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19]

Journal of Human and Clinical Genetics
Amyloid beta
Yeast for the initial studies of Aβ
Findings
Aβ Clioquinol
Aβ Tyramine
Concluding Remarks and Future Approaches of Utilising Yeast to Study AD
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.